This site is intended for health professionals only

Sunday 21 July 2019
Share |

Novartis UK oncology comments on European Commission approval of CART-T therapy Kymriah

Novartis UK Oncology statement on Novartis receiving European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel)
 
"Today’s (27 August) approval by the European Commission of Kymriah® (tisagenlecleucel), the only CAR-T therapy licensed in two different types of blood cancers, moves us one step closer to providing this revolutionary therapy to appropriate patients in the UK. 
 
 
 
"This one-time therapy, specifically custom-made for each individual patient using their own immune cells, has the potential to extend survival and improve quality of life for those children and adults who did not respond to other treatments and whose prognosis is bleak.
 
 
"We continue to follow the UK reimbursement process and are proud to be playing our part to ensure UK patients will have access to and benefit from this life-saving treatment. Together with the NHS, we are working closely to build a foundation to support adoption of medical innovation”, said Mari Scheiffele, Novartis Oncology General Manager, UK & Ireland."
 
 
The full Global release can be viewed here.